Tirbanibulin 1% ointment represents an effective, well-tolerated and innovative field therapy for AK, with a short regimen that fosters adherence and maintains safety even during periods of high UV exposure. The results of this cohort multicenter Italian study endorse tirbanibulin as a compelling therapeutic option throughout the year, including the warmer months. Future prospective studies should further refine follow-up protocols and evaluate the long-term durability of clinical response.
Tirbanibulin 1% real‐world use in 679 actinic keratoses patients during warm season ( SUMM ‐ AK study)
Addari, G.Data Curation
;Atzori, L.Writing – Review & Editing
;
2025-01-01
Abstract
Tirbanibulin 1% ointment represents an effective, well-tolerated and innovative field therapy for AK, with a short regimen that fosters adherence and maintains safety even during periods of high UV exposure. The results of this cohort multicenter Italian study endorse tirbanibulin as a compelling therapeutic option throughout the year, including the warmer months. Future prospective studies should further refine follow-up protocols and evaluate the long-term durability of clinical response.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
